214 related articles for article (PubMed ID: 21083023)
1. Late complications after hematopoietic stem cell transplantation.
Tichelli A; Rovó A; Passweg J; Schwarze CP; Van Lint MT; Arat M; Socié G;
Expert Rev Hematol; 2009 Oct; 2(5):583-601. PubMed ID: 21083023
[TBL] [Abstract][Full Text] [Related]
2. Late pulmonary, cardiovascular, and renal complications after hematopoietic stem cell transplantation and recommended screening practices.
Tichelli A; Rovó A; Gratwohl A
Hematology Am Soc Hematol Educ Program; 2008; ():125-33. PubMed ID: 19074070
[TBL] [Abstract][Full Text] [Related]
3. Late effects after hematopoietic stem cell transplantation--critical issues.
Tichelli A; Rovó A; Socié G
Curr Probl Dermatol; 2012; 43():132-49. PubMed ID: 22377926
[TBL] [Abstract][Full Text] [Related]
4. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
5. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
6. The burden of cure: long-term side effects following hematopoietic stem cell transplantation (HSCT) in children.
Baker KS; Bresters D; Sande JE
Pediatr Clin North Am; 2010 Feb; 57(1):323-42. PubMed ID: 20307723
[TBL] [Abstract][Full Text] [Related]
7. Impact of cumulative anthracycline dose, preparative regimen and chronic graft-versus-host disease on pulmonary and cardiac function in children 5 years after allogeneic hematopoietic stem cell transplantation: a prospective evaluation on behalf of the EBMT Pediatric Diseases and Late Effects Working Parties.
Uderzo C; Pillon M; Corti P; Tridello G; Tana F; Zintl F; Nysom K; Galambrun C; Fagioli F; Varotto S; Messina C; Verdeguer A; Urban C; Faraci M; Dini G; Fedeli S; Tichelli A; Rovelli A; Socié G
Bone Marrow Transplant; 2007 Jun; 39(11):667-75. PubMed ID: 17401396
[TBL] [Abstract][Full Text] [Related]
8. [Thyroid gland dysfunction, disorders of somatic and sexual development, disturbances of fertility after hematopoietic stem cell transplantation].
Wędrychowicz A; Starzyk J
Pediatr Endocrinol Diabetes Metab; 2013; 19(1):29-34. PubMed ID: 23739647
[TBL] [Abstract][Full Text] [Related]
9. Function of the hypothalamic-pituitary-gonadal axis in long-term survivors of hematopoietic stem cell transplantation for hematological diseases.
Somali M; Mpatakoias V; Avramides A; Sakellari I; Kaloyannidis P; Smias C; Anagnostopoulos A; Kourtis A; Rousso D; Panidis D; Vagenakis A
Gynecol Endocrinol; 2005 Jul; 21(1):18-26. PubMed ID: 16048797
[TBL] [Abstract][Full Text] [Related]
10. [The late effects in patients treated with allogeneic hematopoietic stem cell transplantation].
Roziaková L; Bojtárová E; Mistrík M; Mladosievicová B
Klin Onkol; 2011; 24(6):453-9. PubMed ID: 22257235
[TBL] [Abstract][Full Text] [Related]
11. Late effects following hematopoietic cell transplantation for children.
Dahllöf G; Hingorani SR; Sanders JE
Biol Blood Marrow Transplant; 2008 Jan; 14(1 Suppl 1):88-93. PubMed ID: 18162227
[TBL] [Abstract][Full Text] [Related]
12. Late cardiovascular events after allogeneic hematopoietic stem cell transplantation: a retrospective multicenter study of the Late Effects Working Party of the European Group for Blood and Marrow Transplantation.
Tichelli A; Passweg J; Wójcik D; Rovó A; Harousseau JL; Masszi T; Zander A; Békássy A; Crawley C; Arat M; Sica S; Lutz P; Socié G;
Haematologica; 2008 Aug; 93(8):1203-10. PubMed ID: 18556401
[TBL] [Abstract][Full Text] [Related]
13. Time to explore preventive and novel therapies for bronchiolitis obliterans syndrome after allogeneic hematopoietic stem cell transplantation.
Sengsayadeth SM; Srivastava S; Jagasia M; Savani BN
Biol Blood Marrow Transplant; 2012 Oct; 18(10):1479-87. PubMed ID: 22449611
[TBL] [Abstract][Full Text] [Related]
14. Long-term outcome after allo-SCT: close follow-up on a large cohort treated with myeloablative regimens.
Abou-Mourad YR; Lau BC; Barnett MJ; Forrest DL; Hogge DE; Nantel SH; Nevill TJ; Shepherd JD; Smith CA; Song KW; Sutherland HJ; Toze CL; Lavoie JC
Bone Marrow Transplant; 2010 Feb; 45(2):295-302. PubMed ID: 19597425
[TBL] [Abstract][Full Text] [Related]
15. Predicting factors for admission to an intensive care unit and clinical outcome in pediatric patients receiving hematopoietic stem cell transplantation.
Diaz MA; Vicent MG; Prudencio M; Rodriguez F; Marin C; Serrano A; Sevilla J; Casado J; Madero L
Haematologica; 2002 Mar; 87(3):292-8. PubMed ID: 11869942
[TBL] [Abstract][Full Text] [Related]
16. Survivorship issues in hematopoietic stem cell transplantation.
Buchsel PC
Semin Oncol Nurs; 2009 May; 25(2):159-69. PubMed ID: 19411019
[TBL] [Abstract][Full Text] [Related]
17. Graft versus host-associated pulmonary disease and other idiopathic pulmonary complications after hematopoietic stem cell transplant.
Watkins TR; Chien JW; Crawford SW
Semin Respir Crit Care Med; 2005 Oct; 26(5):482-9. PubMed ID: 16267699
[TBL] [Abstract][Full Text] [Related]
18. Graft-versus-host disease: review and nursing implications.
Mattson MR
Clin J Oncol Nurs; 2007 Jun; 11(3):325-8. PubMed ID: 17623617
[TBL] [Abstract][Full Text] [Related]
19. The A-B-C of haematopoietic stem cell transplantation.
Rafeah NT; Fadilah SA
Med J Malaysia; 2009 Mar; 64(1):94-100; quiz 101. PubMed ID: 19852335
[TBL] [Abstract][Full Text] [Related]
20. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
